Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 14
2008 13
2009 9
2010 17
2011 18
2012 16
2013 15
2014 17
2015 24
2016 20
2017 17
2018 18
2019 19
2020 12
2021 11
2022 10
2023 10
2024 10
2025 8
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

255 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Pharmacokinetics of once-daily darunavir/ritonavir in second-line treatment in African children with HIV.
Tsirizani L, Mohsenian Naghani S, Waalewijn H, Szubert A, Mulenga V, Chabala C, Bwakura-Dangarembizi M, Chitsamatanga M, Rutebarika DA, Musiime V, Kasozi M, Lugemwa A, Monkiewicz LN, McIlleron HM, Burger DM, Gibb DM, Denti P, Wasmann RE, Colbers A. Tsirizani L, et al. J Antimicrob Chemother. 2024 Nov 4;79(11):2990-2998. doi: 10.1093/jac/dkae319. J Antimicrob Chemother. 2024. PMID: 39302766 Free PMC article. Clinical Trial.
BACKGROUND: Darunavir is a potent HIV protease inhibitor with a high barrier to resistance. We conducted a nested pharmacokinetic sub-study within CHAPAS-4 to evaluate darunavir exposure in African children with HIV, taking once-daily darunavir/ritonavir for …
BACKGROUND: Darunavir is a potent HIV protease inhibitor with a high barrier to resistance. We conducted a nested pharmacokinetic sub …
Assessing darunavir/ritonavir-based therapy in a racially diverse population: 48-week outcomes from GRACE.
Smith KY, Garcia F, Kumar P, Currier JS, Ryan R, Falcon R, Mrus J, Squires K. Smith KY, et al. J Natl Med Assoc. 2012 Jul-Aug;104(7-8):366-76. doi: 10.1016/s0027-9684(15)30179-6. J Natl Med Assoc. 2012. PMID: 23092052 Clinical Trial.
The multivariate analysis revealed that being of a nonblack race was significantly associated with improved response (P = .009). Overall, darunavir/ritonavir-based therapy was well tolerated, regardless of race. Diarrhea, nausea, and rash were the most commonly reported gr …
The multivariate analysis revealed that being of a nonblack race was significantly associated with improved response (P = .009). Overall, …
Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.
Elliot ER, Cerrone M, Challenger E, Else L, Amara A, Bisdomini E, Khoo S, Owen A, Boffito M. Elliot ER, et al. J Antimicrob Chemother. 2019 Jan 1;74(1):149-156. doi: 10.1093/jac/dky384. J Antimicrob Chemother. 2019. PMID: 30272231 Clinical Trial.
BACKGROUND: Dolutegravir combined with darunavir/cobicistat is a promising NRTI-sparing and/or salvage strategy for the treatment of HIV-1 infection. ...Group 1 received dolutegravir (50 mg) once daily for 14 days followed by a 7 day washout, then a 14 day dolutegravir/ …
BACKGROUND: Dolutegravir combined with darunavir/cobicistat is a promising NRTI-sparing and/or salvage strategy for the treatment of …
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive (AMBER) and virologically suppressed (EMERALD) participants with neurological and/or psychiatric comorbidities: Week 96 subgroup analysis.
Dunn K, Bushen J, Luo D, Cai J, Simonson RB, Anderson D. Dunn K, et al. HIV Med. 2023 Mar;24(3):279-289. doi: 10.1111/hiv.13377. Epub 2022 Aug 15. HIV Med. 2023. PMID: 36912173 Free article. Clinical Trial.
METHODS: AMBER (treatment-naive population) and EMERALD (virologically suppressed population) were phase III randomized studies of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg. ...
METHODS: AMBER (treatment-naive population) and EMERALD (virologically suppressed population) were phase III randomized studies of daruna …
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive patients with HIV-1: subgroup analyses of the phase 3 AMBER study.
Rashbaum B, Spinner CD, McDonald C, Mussini C, Jezorwski J, Luo D, Van Landuyt E, Brown K, Wong EY. Rashbaum B, et al. HIV Res Clin Pract. 2019 Feb;20(1):24-33. doi: 10.1080/15284336.2019.1608714. Epub 2019 May 29. HIV Res Clin Pract. 2019. PMID: 31303147 Free article. Clinical Trial.
Background: The once-daily, single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is approved for the treatment of HIV-1 infection. The 48-week efficacy and safety of D/C/F/TAF versus darunavir/cobicistat + emtr …
Background: The once-daily, single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 …
Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D(2)EFT): an open-label, randomised, phase 3b/4 trial.
D2EFT Study Group. D2EFT Study Group. Lancet HIV. 2024 Jul;11(7):e436-e448. doi: 10.1016/S2352-3018(24)00089-4. Epub 2024 May 21. Lancet HIV. 2024. PMID: 38788744 Free PMC article. Clinical Trial.
It was originally designed to compare recommended standard of care (ritonavir-boosted darunavir [800 mg darunavir plus 100 mg ritonavir once daily] plus two nucleoside reverse transcriptase inhibitors [NRTIs; dosed once or twice daily]) with a novel nucleoside spari …
It was originally designed to compare recommended standard of care (ritonavir-boosted darunavir [800 mg darunavir plus 100 mg …
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
Huhn GD, Eron JJ, Girard PM, Orkin C, Molina JM, DeJesus E, Petrovic R, Luo D, Van Landuyt E, Lathouwers E, Nettles RE, Brown K, Wong EY. Huhn GD, et al. AIDS Res Ther. 2019 Aug 29;16(1):23. doi: 10.1186/s12981-019-0235-1. AIDS Res Ther. 2019. PMID: 31464642 Free PMC article. Clinical Trial.
BACKGROUND: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is a once-daily, single-tablet regimen for treatment of HIV-1 infection. ...Outcomes were examined for prespecified subgroups by age ( /> 50 years), gender, race (black/no …
BACKGROUND: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is a once-daily, single-tablet reg …
Efficacy and safety of boosted darunavir-based antiretroviral therapy in HIV-1-positive patients: results from a meta-analysis of clinical trials.
Antinori A, Lazzarin A, Uglietti A, Palma M, Mancusi D, Termini R. Antinori A, et al. Sci Rep. 2018 Mar 27;8(1):5288. doi: 10.1038/s41598-018-23375-6. Sci Rep. 2018. PMID: 29588457 Free PMC article.
Darunavir/ritonavir (DRV/r) is a second-generation protease inhibitor used in treatment-naive and -experienced HIV-positive adult patients. ...
Darunavir/ritonavir (DRV/r) is a second-generation protease inhibitor used in treatment-naive and -experienced HIV-positive adult pat …
Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV.
Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, Kaimal A, Mirembe G, Tukamushabe P, Ategeka G, Hakim J, Mugerwa H, Siika A, Asienzo J, Castelnuovo B, Kiragga A, Kambugu A; NADIA Trial Team. Paton NI, et al. N Engl J Med. 2021 Jul 22;385(4):330-341. doi: 10.1056/NEJMoa2101609. N Engl J Med. 2021. PMID: 34289276 Clinical Trial.
METHODS: In a two-by-two factorial, open-label, noninferiority trial, we randomly assigned patients for whom first-line therapy was failing (HIV-1 viral load, 1000 copies per milliliter) to receive dolutegravir or ritonavir-boosted darunavir and to receive tenofovir or zi …
METHODS: In a two-by-two factorial, open-label, noninferiority trial, we randomly assigned patients for whom first-line therapy was failing …
Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial.
Pressiat C, Hirt D, Treluyer JM, Zheng Y, Morlat P, Naqvi A, Tran L, Viard JP, Avettand-Fenoel V, Rouzioux C, Meyer L, Cheret A; OPTIPRIM Study Group. Pressiat C, et al. J Antimicrob Chemother. 2018 Apr 1;73(4):1020-1024. doi: 10.1093/jac/dkx498. J Antimicrob Chemother. 2018. PMID: 29365125 Clinical Trial.
BACKGROUND: The OPTIPRIM-ANRS 147 trial compared intensive combination ART (darunavir/ritonavir, tenofovir disoproxil fumarate/emtricitabine, raltegravir and maraviroc) started early during primary HIV-1 infection with standard tritherapy with darunavir/ritonavir, t …
BACKGROUND: The OPTIPRIM-ANRS 147 trial compared intensive combination ART (darunavir/ritonavir, tenofovir disoproxil fumarate/emtric …
255 results